Remus PharmaceuticalsShare price, financial results, shareholding and management
- Market cap
- ₹943 cr
- Stock P/E
- 20.5peers 28.1
- Book value
- ₹298
- Price to book
- 2.69
- EV / operating profit
- 16.8
- Market cap to sales
- 1.10
- ROCE · FY26
- 18.3%
- ROE · FY26
- 15.2%
- ROE, 3-year average
- 20.3%
- Operating margin · FY26
- 7.0%peers 10.2%
- Sales growth, 3 years
- 166.7%
- Profit growth, 3 years
- 79.2%
- Debt to equity
- 0.08peers 0.34
- Borrowings
- ₹27 cr
- Interest cover
- 60.0×
- Cash from business / op. profit
- 32%
- Debtor days
- 60
- Pledged
- 0.00%
- Promoter holding
- 70.95%
- Change in promoter holding
- +0.04 pts
- Shareholders
- 2,009
- 52-week high / low
- ₹1,039 / ₹580
- Dividend yield
- Paid
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Remus Pharmaceuticals share price chart
Close on 6 Nov 2026 · -4.69% on the day · Vol 7,700
Daily prices to 6 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 6 Nov 2026
- 1 month
- -6.5%
- 3 months
- -5.0%
- 6 months
- +3.4%
- 1 year
- -1.3%
- Traded a day, 20 days
- ₹0.63 cr
- Taken for delivery
- 78%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +38% | +21% |
| 3 years, a year | +167% | +79% |
| Latest half, H2 FY26 | +30% | +19% |
About Remus Pharmaceuticals: business, products and customers
Remus Pharmaceuticals markets medicines made for it by approved drug makers, supplying distributors, governments and pharmacies in Latin America, Asia, the Middle East and Africa. A part owned arm in the United States also supplies branded medicines to drug companies and research groups, and its shares trade on NSE Emerge.
Remus Pharmaceuticals was set up in Ahmedabad in 2015 and exports finished medicines, such as tablets, capsules, injections, inhalers and soft gels, to more than 40 countries, with its strongest presence in Latin America. It does not run its own factories: products are made on contract by manufacturers it has checked and approved, all in India so far, while Remus holds the product registration in each country. The company says a registration takes six months to three years, and its in house regulatory team prepares and files the dossiers.
The export business reaches buyers in two ways. Distributors take products under Remus registrations (B2B, ₹83.0 cr in FY26), and the company's own Relius subsidiaries in Bolivia and Guatemala market products under its own brands to pharmacies and patients (B2C, ₹14.1 cr in FY26, up from ₹3.4 cr). It also supplies government tenders, recently in Nicaragua, Saudi Arabia and North Macedonia.
Read more about the business
In 2024 Remus acquired control of Espee Global Holdings LLC in the United States, which distributes reference listed drugs to drug makers, research groups and government agencies; Remus holds 56.67% of it. This US arm is the largest part of group revenue and works on thin margins, so group revenue of ₹853.6 cr in FY26 sits beside revenue of ₹94.0 cr for Remus on its own.
What is new: filings for semaglutide tablets and injections in markets without a patent, in licensed filgrastim injections from a US maker for the Philippines and Vietnam, a cleared inspection by Peru's regulator in February 2026, four new markets in FY26, and a new subsidiary for clinical trial services set up during FY26.
From the offer document (2023), the FY26 annual report, the May 2026 investor presentation, the May 2026 earnings call and the May 2026 press release.
Read the deeper study ↓In its favour
- Sales have grown very fast: 167% a year over three years.
- It has little debt for its size: debt to equity 0.08.
- The promoters own a large part of the company: 70.95%.
- It paid a dividend in the past year.
To watch
- The 40 further own brand launches in Bolivia planned over six months from May 2026 (Press release, May 2026, p.3).
- Semaglutide sales in three to four countries without a patent, which the Managing Director said were planned for FY27 (Earnings call, May 2026, p.7).
- The start of operations at Espee Global Clinical Trial Services, expected during FY27 (Earnings call, May 2026, p.10; Annual report FY26, p.26).
- Collection of group trade receivables of ₹139.8 cr at March 2026 (Investor presentation, May 2026, p.35).
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Remus Pharmaceuticals revenue and profit growth
Half-yearly results · Profit and lossSales have grown very fast. Last year profit grew more slowly than sales, so the profit kept from each rupee of sales slipped.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.
Remus Pharmaceuticals half-yearly results
SME companies report every six months · ₹ crore
| H1FY23 | H2FY23 | H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 20 | 25 | 29 | 185 | 273 | 348 | 400 | 453 |
| Expenses | 16 | 19 | 20 | 165 | 252 | 323 | 373 | 424 |
| Operating profit | 5 | 6 | 9 | 20 | 20 | 25 | 27 | 30 |
| OPM | 23.0% | 23.0% | 32.0% | 11.0% | 8.0% | 7.0% | 7.0% | 7.0% |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| Profit before tax | 6 | 6 | 10 | 22 | 22 | 25 | 28 | 31 |
| Net profit | 4 | 4 | 6 | 19 | 19 | 21 | 22 | 25 |
Remus Pharmaceuticals profit and loss
Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Sales | 12 | 18 | 25 | 45 | 213 | 620 | 854 |
| Expenses | 12 | 18 | 21 | 34 | 184 | 575 | 797 |
| Operating profit | 0 | 1 | 4 | 11 | 29 | 46 | 57 |
| OPM | 3.3% | 4.3% | 17.0% | 23.0% | 14.0% | 7.0% | 7.0% |
| Other income | 1 | 1 | 1 | 2 | 3 | 5 | 7 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Exceptional and other items | · | -1 | · | -2 | -1 | · | · |
| Profit before tax | 1 | 1 | 5 | 11 | 30 | 47 | 59 |
| Tax rate | 0.0% | 0.0% | 40.0% | 27.3% | 20.0% | 19.1% | 22.0% |
| Net profit | 1 | 1 | 3 | 8 | 24 | 38 | 46 |
| EPS ₹ | · | · | 4.29 | 9.66 | 17.69 | 24.64 | 31.39 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 3.0% | 4.0% | 3.0% | 2.0% |
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
Remus Pharmaceuticals profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a moderate return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Operating margin | 3.3% | 4.3% | 17.0% | 23.0% | 14.0% | 7.0% | 7.0% |
| Tax rate | 0.0% | 0.0% | 40.0% | 27.3% | 20.0% | 19.1% | 22.0% |
| ROCE | · | 39.8% | 99.9% | 64.7% | 30.3% | 21.3% | 18.3% |
| ROE | · | 39.8% | 59.9% | 61.5% | 27.3% | 18.4% | 15.2% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 3.0% | 4.0% | 3.0% | 2.0% |
Remus Pharmaceuticals debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. Customers pay faster than they did in FY24, which frees up the company's money.
Bars below the line are cash going out.
Remus Pharmaceuticals balance sheet
At each 31 March · ₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Equity capital | 0.01 | 0.01 | 1 | 1 | 1 | 6 | 12 |
| Reserves | 2 | 3 | 6 | 18 | 156 | 250 | 339 |
| Net worth | 2.01 | 3.01 | 7 | 19 | 157 | 256 | 351 |
| Borrowings | 0 | 0 | 0 | 8 | 14 | 23 | 27 |
| Other liabilities | 2.99 | 7.99 | 9 | 8 | 162 | 154 | 201 |
| Total liabilities | 5 | 11 | 16 | 35 | 333 | 433 | 579 |
| Fixed assets | 0 | 0 | 0 | 3 | 14 | 16 | 18 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Investments | 0 | 0 | 3 | 21 | 105 | 186 | 275 |
| Other assets | 5 | 11 | 13 | 11 | 214 | 231 | 278 |
| Receivables | · | · | · | · | · | 108.03 | 139.84 |
| Inventory | · | · | · | · | · | 51.56 | 72.06 |
| Cash | · | · | · | · | · | 8.14 | 12.88 |
| Trade payables | · | · | · | · | · | 71.29 | 76.04 |
Remus Pharmaceuticals cash flow
₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | 0 | 5 | 5 | 4 | 7 | 18 |
| Cash from investing | -1 | 0 | -5 | -15 | -9 | -11 | -15 |
| Cash from financing | 0 | 0 | 0 | 12 | 24 | 6 | 1 |
| Net cash flow | 0 | 0 | 0 | 2 | 19 | 2 | 4 |
| Capital spending | · | · | · | · | · | 3.98 | 14.57 |
Working capital
Days
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 50 | 71 | 43 | 39 | 198 | 64 | 60 |
| Inventory days | 23 | 36 | 47 | 5 | 96 | 35 | 35 |
| Days payable | 68 | 164 | 139 | 60 | 209 | 49 | 37 |
| Cash conversion cycle | 5 | -56 | -48 | -16 | 85 | 50 | 58 |
| Working capital days | 19 | -20 | -39 | 1 | 98 | 54 | 49 |
Remus Pharmaceuticals peers and competitors
Listed SME companies in the same industryBy sales, Remus Pharmaceuticals is number 1 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Remus Pharmaceuticals | 943 | 20.5 | 854 | 46 | 7.0% | 0.08 |
| Accent Microcell | 1,669 | 37.9 | 349 | 44 | 16.0% | 0.00 |
| Sat Kartar Life | 220 | 12.9 | 201 | 17 | 12.0% | 0.03 |
| Infinium Pharmachem | 471 | 38.7 | 190 | 12.2 | 11.4% | 0.19 |
| Zenith Drugs | 68 | 17.2 | 171 | 3.9 | 7.1% | 0.75 |
| Mono Pharmacare | 16 | 44.6 | 166 | 0.4 | 2.4% | 1.79 |
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Median of the 10 others | 281 | 28.1 | 157 | 9.3 | 10.2% | 0.34 |
Remus Pharmaceuticals shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little more than in the first filing shown. Foreign and Indian funds own a noticeable share. The number of shareholders has grown a lot.
Remus Pharmaceuticals shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 23 | Mar 24 | Jun 24 | Sep 24 | Mar 25 | Jul 25 | Sep 25 | Mar 26 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.61% | 70.60% | 70.66% | 70.84% | 70.85% | 70.85% | 70.91% | 70.95% |
| Foreign investors (FIIs) | 2.38% | 3.25% | 3.00% | 3.16% | 4.77% | 5.03% | 5.02% | 5.28% |
| Indian institutions (DIIs) | 0.71% | 0.67% | 0.73% | 0.77% | 0.77% | 0.79% | 0.77% | 0.83% |
| HNIs (over ₹2 lakh each) | 0.00% | 0.00% | 5.43% | 4.96% | 4.77% | 7.35% | 7.40% | 6.91% |
| Small holders (up to ₹2 lakh) | 21.15% | 20.54% | 15.47% | 15.52% | 14.41% | 11.54% | 11.38% | 11.59% |
| Companies and others | 6.15% | 4.94% | 4.71% | 4.75% | 4.43% | 4.44% | 4.52% | 4.44% |
| Number of shareholders | 856 | 1,124 | 1,577 | 1,753 | 1,878 | 2,017 | 2,032 | 2,009 |
The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.
Remus Pharmaceuticals study: the business from its own documents
Read from 13 of the company's own documentsRemus Pharmaceuticals so far
From the company's own record
- 29 May 2023Listed on NSE Emerge
- 7 Oct 2026Shareholders approved
- 31 March 2026Promoters at 70.95%
- 11 Oct 2024Highest close since listing, ₹1,198.02
Remus Pharmaceuticals key facts from the filings
Each figure with the document it comes from
- Registered products
- 903+
- Products registered with health regulators abroad in 2026, up from 275 in 2021; more than 430 of them are on sale and over 850 dossiers are ready to file.Investor presentation, May 2026, p.3 and p.16
- Countries
- 40+
- Countries where the company exports finished medicines, with four new markets added in FY26: Myanmar, Nicaragua, North Macedonia and Madagascar.Earnings call, May 2026, p.4 and p.6; Investor presentation, May 2026, p.28
- Own business and group
- ₹94.0 cr of ₹853.6 cr
- FY26 revenue of Remus on its own against revenue for the whole group; most of the difference comes from the US distribution arm.Investor presentation, May 2026, p.30 and p.32; Earnings call, May 2026, p.10
- Margin, own and group
- 31.6% and 6.6%
- FY26 operating margin of Remus on its own and of the whole group, which includes the low margin US distribution business.Investor presentation, May 2026, p.30 and p.32
- US arm
- 56.67%
- The share Remus holds in Espee Global Holdings LLC, acquired in 2024; the rest of its profit belongs to other owners, so group profit for Remus shareholders was ₹37.0 cr of ₹46.2 cr in FY26.Annual report FY26, p.26; Investor presentation, May 2026, p.6 and p.32
Show 5 more facts
- Own brand sales
- ₹14.1 cr
- FY26 sales through the Relius subsidiaries in Bolivia and Guatemala, up from ₹3.4 cr in FY25, across 41 products.Investor presentation, May 2026, p.15
- Contract makers
- About 20 active
- Manufacturers the company works with closely, out of about 34 it has approved; all current work is done in India.Earnings call, May 2026, p.16
- Order book
- ₹170 cr
- Orders in hand for the group as stated in August 2025, the only order book figure in the filings read.Press release, August 2025, p.2
- Top ten customers
- 73.7%
- Share of revenue from the ten largest customers in the nine months to December 2022, before the US arm joined; no later figure is given.Offer document, p.93
- Finance chief
- Resigned
- Chief Financial Officer Anjali Shah resigned with effect from 8 July 2026 to pursue other professional opportunities.Announcement, 22 June 2026, p.1
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
In the May 2026 call, Managing Director Arpit Shah said the company plans to start semaglutide sales in three to four countries without a patent during FY27, and Chief Financial Officer Anjali Shah said the clinical trial services subsidiary was expected to start operations during the year. The company says it launched 26 own brand products in Bolivia, with 40 more planned over six months from May 2026. The only order book stated, in August 2025, was ₹170 cr for the group.
| What management said | When | What happened |
|---|---|---|
| Own brand (D2C) channel to double its revenue | Aug 2025 press release | B2C sales rose to ₹14.1 cr in FY26 from ₹3.4 cr |
| 40 more B2C launches in Bolivia over six months | May 2026 press release | No update in the filings read |
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
Remus Pharmaceuticals earns most of its profit by registering medicines abroad and supplying them under those registrations, a business with wide margins that needs few fixed assets.
Most of its revenue, though, now comes from a part owned US distribution arm with thin margins, and money tied up in unpaid bills and stock has grown with it.
AverageCan it set its own prices?Where Remus owns the registration and the brand, it keeps wide margins. Government tenders and the US distribution arm earn far less.
AverageHow strong is it against rivals?Registrations take a long time to win, which keeps some rivals out, but the company does not make its own products and relies on contract makers.
AverageWho are its customers?Distributors abroad, government tenders and pharmacies take the exports; the US arm serves drug makers and research groups. The only customer split on record is old.
WatchDoes it need a lot of money?Few fixed assets are needed, but unpaid bills and stock held for US customers have grown, so little of the profit has turned into cash.
StrongCan it keep finding new work?The bank of registered products and filings keeps growing, and the company keeps adding countries and tenders.
AverageDo good and bad years swing a lot?Revenue has grown each year, but much of the export business sits in countries where politics and currencies can delay launches and payments.
Who runs Remus Pharmaceuticals?
Promoters, directors and officers; tap a name for the background
ADArpit Deepakkumar ShahPromoter and Managing Director · holds 17.66%
An engineering graduate who has been a director since the company was set up and Managing Director since January 2023. Leads business development, alliances, strategic decisions and portfolio expansion, and earlier worked for a large US based conglomerate. The offer document states that Arpit Deepakkumar Shah is the spouse of Roma Vinodbhai Shah.
Offer document, p.173 and p.176 to 177; Investor presentation, May 2026, p.8SJSwapnil Jatinbhai ShahPromoter, Chairman and Non-Executive Director · holds 16.97%
Holds a Bachelor of Engineering (Chemical), an MBA from Hofstra University, New York, and a diploma in business entrepreneurship from the Entrepreneurship Development Institute of India. A director since the company was set up, involved in business development and corporate strategy; earlier a strategist at a NASDAQ listed fintech company. The offer document states that Swapnil Jatinbhai Shah is the spouse of Anar Swapnil Shah.
Offer document, p.176 to 177; Investor presentation, May 2026, p.8; Annual report FY26, p.26RVRoma Vinodbhai ShahPromoter and Whole Time Director · holds 17.21%
Holds a Bachelor of Pharmacy from Gujarat University and a Master of Science in Pharmaceutical Manufacturing from Stevens Institute of Technology, New Jersey. A director since the company was set up, handling regulatory matters, product registrations and research, and credited with building the company's consultancy vertical.
Offer document, p.176; Investor presentation, May 2026, p.8ASAnar Swapnil ShahPromoter and Non-Executive Director · holds 16.97%
A dentist by training with a Bachelor of Dental Surgery from Bharati Vidyapeeth Deemed University and an MBA from Nirma University. On the board since 2020; moved from executive to non-executive director in May 2025 and advises the board on human resources.
Offer document, p.176; Annual report FY26, p.22VCVishrut Chandramauli PathakIndependent Director
Holds MBAs from Gujarat University and St. John's University and a postgraduate diploma in financial statement analysis from New York University; works in investment management and corporate finance. On the board since January 2023.
Offer document, p.176 to 177; Investor presentation, May 2026, p.8SSSanjana Sanjeev ShahIndependent Director
A Chartered Accountant with a Bachelor of Commerce from H. L. College of Commerce, Ahmedabad, working in accounts and financial management. On the board since January 2023.
Offer document, p.176 to 177; Investor presentation, May 2026, p.8ANAshutosh Naginbhai ValaniAdditional Independent Director
Appointed in September 2026. Holds a Master of International Business from Brunel University, London, with around 18 years of experience; co-founder and director of Renee Cosmetics and earlier founder of the Beardo and Villain brands.
Annual report FY26, p.21 to 22Remus Pharmaceuticals latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹453 cr (+30%), net profit ₹25 cr (+19%) on H2 FY25.
- Shareholding, 31 March 2026: promoters 70.91% to 70.95%.
- Main board migration: shareholders approved, 7 Oct 2026 (migration tracker).
Remus Pharmaceuticals announcements
103 on record, latest first; each opens the filing on the exchange
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Disclosure under Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026PDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026PDF ↗
- Shareholders meetingScrutinizer report and voting results for Postal BallotPDF ↗
- Shareholders meetingScrutinizer Report and Voting results of 11th Annual General MeetingPDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on September 29, 2026PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Copy of Newspaper PublicationCopy of Newspaper PublicationPDF ↗
- Record Datethat Record date for the purpose of Dividend is 22-Sep-2026PDF ↗
- Shareholders meetingNotice of Annual General Meeting to be held on September 29, 2026PDF ↗
- Copy of Newspaper PublicationCopy of Newspaper PublicationPDF ↗
- Shareholders meetingNotice of Postal BallotPDF ↗
- Copy of Newspaper PublicationCopy of Newspaper PublicationPDF ↗
Remus Pharmaceuticals annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Remus Pharmaceuticals share split, bonus and dividends
From the corporate actions the company announces on the exchange
- DividendDIVIDEND - RE 0.50 PER SHAREex-date 22 Sept 2026
- DividendINTERIM DIVIDEND - RE 0.50 PER SHAREex-date 14 Nov 2025
- DividendDIVIDEND - RE 0.50 PER SHAREex-date 18 Sept 2025
- Bonus issueBONUS 1:1ex-date 4 July 2025
- DividendINTERIM DIVIDEND - RE 1 PER SHAREex-date 19 Nov 2024
- Bonus issueBONUS 3:1ex-date 6 June 2024
- DividendINTERIM DIVIDEND - RS 4 PER SHAREex-date 2 May 2024
- DividendINTERIM DIVIDEND - RS 2 PER SHAREex-date 27 Oct 2023
- DividendDIVIDEND - RS 2 PER SHAREex-date 15 Sept 2023
Checks we ran on Remus Pharmaceuticals' data · 10
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- !For FY25, FY26, H2FY25, H1FY26, H2FY26 the exchange filing's profit lines do not add up as read, so the figures shown are from the results page instead.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,17,84,000 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY20 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Remus Pharmaceuticals
What does Remus Pharmaceuticals do?
Remus Pharmaceuticals markets medicines made for it by approved drug makers, supplying distributors, governments and pharmacies in Latin America, Asia, the Middle East and Africa. A part owned arm in the United States also supplies branded medicines to drug companies and research groups, and its shares trade on NSE Emerge.
What is the share price of Remus Pharmaceuticals?
₹800 at the close on 6 Nov 2026, from the exchange's daily figures.
What is the market cap of Remus Pharmaceuticals?
₹943 cr at the close on 6 Nov 2026, on 1,17,84,000 shares.
What is the P/E of Remus Pharmaceuticals?
20.5 times FY26 profit at the close on 6 Nov 2026 (our arithmetic).
What are Remus Pharmaceuticals' revenue and profit?
Revenue ₹854 cr and profit after tax ₹46 cr in FY26.
Who are the promoters of Remus Pharmaceuticals?
Arpit Deepakkumar Shah, Swapnil Jatinbhai Shah, Roma Vinodbhai Shah, Anar Swapnil Shah; promoters held 70.95% at 31 March 2026.
What is Remus Pharmaceuticals' website?
www.remuspharma.com
More SME companies like Remus Pharmaceuticals
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Aptus PharmaAPPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹798 cr
- Accent MicrocellACCENTMIC · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹1,466 cr
- Influx HealthtechINFLUX · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2025Market cap ₹581 cr
- Trident LifelineTLL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹495 cr
- KRM AyurvedaKRMAYURVED · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2026Market cap ₹485 cr
- Infinium PharmachemINFINIUM · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹435 cr
Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2023 →
Built from 3 earnings call transcripts, 3 investor presentations, 3 press releases, 2 annual reports, 1 offer document, 1 result filing, 103 exchange announcements, 8 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.